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ABSTRACT
Adrenoleukodystrophy (ALD) is an X-linked disorder caused by a defect in the metabolism of long chain fatty
acids leading to demyelination, neurodegeneration, and death. The disease typically presents in young boys and
adolescent boys. Allogeneic bone marrow transplantation has been used to halt progression of the disease.
However, many patients lack suitable HLA- matched related donors and must rely on unmatched donors for
a source of stem cells. The purpose of this study was to evaluate outcomes of unrelated donor umbilical cord
blood transplantation after chemotherapy-based myeloablative conditioning and retrospectively determine if
baseline studies correlate and help predict outcome. Between November 22, 1996, and November 3, 2005, 12
boys with X-linked ALD who lacked HL- matched related donors were referred to Duke University Medical
Center for transplantation. These children were conditioned with myeloablative therapy including busulfan,
cyclophosphamide, and antithymocyte globulin before receiving umbilical cord-blood transplants from unre-
lated donors. Baseline studies of neurophysiologic, neuroimaging, and neurodevelopmental status were per-
formed and patients were subsequently evaluated for survival, engraftment, graft-versus-host disease, and
neurodevelopmental outcomes. A substudy evaluated whether baseline neuroimaging and neurophysiologic
studies correlated with cognitive and motor function and if these studies were predictive of posttransplantation
outcomes. The umbilical cord blood grafts had normal levels of very long chain fatty acids. They delivered a
median of 6.98  107 nucleated cells per kilogram of recipient body weight and were discordant for up to 4 of
6 HLA markers. Neutrophil engraftment occurred at a median of 22.9 days after transplantation. Three
patients had grade II-IV acute graft-versus-host disease; 2 had extensive chronic graft-versus-host disease.
Cumulative incidence of overall survival of the group at 6 months is 66.7% (95% confidence interval 39.9-
93.3%). Median follow-up was 3.3 years (range 12 days to 6.3 years). As previously reported with bone marrow
transplantation, symptomatic patients faired poorly with lower survival and rapid deterioration of neurologic
function. This study included 3 patients transplanted at a very young age (2.6-3.5 years) before the onset of
clinical symptoms who continue to develop at a normal rate for 3-5 years posttransplant. Although baseline
Loes scores correlated with cognitive and motor outcome, neurophysiologic studies failed to show statistically
significant differences. Transplantation of boys with X-linked ALD using partial HLA-matched umbilical cord
blood yields similar results to those previously reported after bone marrow transplantation. Superior outcomes
were seen in neurologically asymptomatic boys less than 3.5 years of age at the time of transplantation. Baseline
Loes scores were a strong predictor of cognitive and motor outcome.
© 2007 American Society for Blood and Marrow Transplantation
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D. Beam et al.666NTRODUCTION
Adrenoleukodystrophy is an X-linked disorder (X-
LD) caused by the deﬁciency of the ABCD1 gene
hat encodes for a peroxisomal protein membrane. It
s associated with the accumulation of very long chain
atty acids (VLCFA) that can be measured in the
lasma for diagnosis. X-ALD affects the testes, adre-
al cortex, and the nervous system. The cerebral form
eads to demyelination and typically affects young
oys who present with behavioral lability, visual im-
airment, seizures, progressive loss of cognitive and
otor function, and death by 10 years of age [1-3]. A
ilder adult form referred to as adrenomyeloneuropa-
hy involves mainly the spinal cord. Hematopoietic
tem cell transplantation (HSCT) arrests progression
f cerebral X-ALD and other leukodystrophies in pa-
ients with early stages of disease [4-7]. However,
any patients cannot identify an appropriately
atched sibling or unrelated adult donor [4,6,7]. Un-
elated donor umbilical cord blood (UCB) has been
hown to successfully reconstitute marrow in children
ollowing allogeneic transplant for malignant and
onmalignant diseases [8-10]. We now report the out-
omes after UCB transplantation in a series of 12 boys
ith X-ALD. We also correlate baseline neurodevel-
pmental, neurophysiologic, and brain imaging ﬁnd-
ngs with functional outcomes.
ETHODS
Between November 22, 1996, and November 3,
005, 12 boys with adrenoleukodystrophy lacking
LA-matched related donors were referred to the
ediatric Bone Marrow Transplant Program at Duke
niversity. All patients were evaluated with a baseline
rain MRI, peripheral nerve conduction velocity
NCV), brainstem auditory evoked responses (BAER),
isual evoked potentials (VEP), electroencephalogram
EEG), and neurodevelopmental evaluations. The di-
gnosis of ALD was conﬁrmed by the presence of
bnormally high levels of long chain fatty acids
LCFA) in the blood measured by capillary gas chro-
atography of pentaﬂuorobenzyl bromide fatty acid
sters [11]. After parental informed consent was ob-
ained, 4 patients were enrolled in the Cord Blood
ransplantation Study (COBLT), 4 patients enrolled
n the COBLT-Extended Access Protocol (COBLT-
AP), and 4 patients were enrolled in an ongoing
ingle-institution study. All were approved by the in-
titutional review board at Duke University Hospital.
he transplant related outcomes of 8 patients trans-
lanted on the COBLT or the COBLT-EAP studies
ere previously reported as part of a larger cohort of
atients with lysosomal storage diseases. These in-
luded survival, engraftment, and graft-versus-host-
isease (GVHD) [10]. Neurophysiologic, neuroimag- tng, or neurodevelopmental outcomes were not
reviously reported in any of the patients.
election of Donors
Cord blood units from unrelated donors were se-
ected from public cord blood banks listing units
hrough the National Marrow Donor Program or the
ew York Blood Center after a search using interme-
iate resolution HLA typing for class I (A and B) and
igh-resolution typing of HLA-DRB1. The units with
he highest number of nucleated cells (minimum, 3 
07 per kilogram of body weight) matching at least 4
f 6 HLA loci were selected and tested for normal
evels of LCFA [11]. Cell dosing was prioritized over
LA matching for unit selection for transplantation.
inal unit selection was based on highest cell dose
ith closest HLA match and normal very long chain
atty acids (VLCFA) levels.
onditioning Regimen
Patients underwent a myeloablative preparative
egimen of busulfan, cyclophosphamide, and antithy-
ocyte globulin as previously described [12-14].
irst-dose pharmacokinetic studies were performed
uring busulfan therapy targeting a steady-state con-
entration (Css) of 600-900 ng/mL. Patients received
henytoin prophylaxis against seizures during therapy
ith busulfan; mesna was administered during cyclo-
hosphamide therapy for prophylaxis against hemor-
hagic cystitis.
ransplantation Procedure
Cryopreserved units of cord blood were thawed
nd processed as previously reported [15]. Thawed
nits were tested for total number of nucleated cells,
lonal hematopoietic progenitor cells, CD3, CD34
ells, ABO, and Rh typing, cell viability, and sterility.
rophylaxis against and Treatment of GVHD
The patients received cyclosporine for 9 months
nd methylprednisolone for 2 to 3 months as prophy-
axis against GVHD. In the absence of chronic
VHD (cGVHD), immune suppression was discon-
inued approximately 1 year posttransplant [10,12,13].
he severity of acute GVHD (aGVHD) was scored
sing standard criteria [16]. Acute grade 1 GVHD of
he skin was treated with topical creams, an escalation
n methylprednisolone, or both. Patients with moder-
te to severe GVHD received pulsed doses of meth-
lprednisolone 500 mg per square meter given intra-
enously every 12 hours for 4 total doses before
VHD treatment was changed from cyclosporine toacrolimus, alone or in combination with daclizumab.
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Outcomes of Unrelated UCBT for X-ALD 667upportive Care
All patients were hospitalized in reverse isola-
ion with high-efﬁciency particulate air ﬁltration.
rophylaxis for pneumocystis carinii, viral, and fun-
al infections were given in a standard fashion. The
rst episode of febrile neutropenia was treated with
road-spectrum antibiotics, and therapy continued
hrough engraftment. Intravenous immunoglobulin
as given weekly through day 100. Continuous low-
ose heparin was infused intravenously as prophy-
axis for veno-occlusive disease (VOD) of the liver
hrough day 28 posttransplant. Patients received
eupogen (10 g/kg/day intravenously) from day
f transplant to engraftment.
linical Studies
Patients were evaluated at baseline and every 6-12
onths with echocardiograms, pulmonary function
ests, ophthalmology, serial brain imaging, and neu-
ophysiologic and neurodevelopmental assessments
including vision, hearing, speech and language, mo-
or, cognitive, and adaptive behavior).
utcome Measures
The outcome measures included engraftment
nd survival, change in neurophysiologic measures
nd 4 domains of neurodevelopmental function:
ognitive, adaptive-behavior, language, and motor
kills.
Engraftment and survival. Engraftment was deﬁned
s the ﬁrst of 3 consecutive days with absolute neu-
rophil count of at least 500 cells per cubic millimeter.
he probability of overall survival (OS) was calculated
ccording to the Kaplan-Meier method. The cutoff
ate for analysis was June 1, 2006.
Neurodevelopmental assessment. Standardized and
alidated neurobehavioral tools were used to assess all
atients at baseline and follow up (Table 1) [17-24].
tandard scores and developmental quotients were
onverted to age-equivalent scores to allow compari-
ons of results among various tests and to identify
evelopment of new skills. Motor, cognitive, recep-
ive, and expressive language and adaptive behavior
ere assessed. Results were compared to norms of
ypically developing children.
able 1. Neurodevelopmental Testing
Domain Before 5 years
ognitive The Capute Scales (CAT/CLAMS) Mullen
Early Learning
anguage Preschool Language Scale—Third and Fo
Edition
otor Peabody Developmental Motor Scales, Se
Edition (PDMS-2)daptive Behavior Scales of Independent Behavior Revised (SIBR)MRI analysis. Two board-certiﬁed neuroradiolo-
ists scored pretransplantation MR studies using the
odiﬁed Loes scoring system in a consensus manner
n a single scoring session [25]. Readers were aware of
atient age (which was needed to assess appearance of
hite matter relative to the normal population) but were
linded to all other clinical information. Images were
eviewed on a PACS workstation in all patients except 1,
hich allowed windowing of images to optimize signal
ntensity of structures for scoring and also direct corre-
ation of structures in different imaging planes.
Neurophysiologic Studies. EEG, nerve conduction
eolcity (NCV), visual evoked potential (VEP), and
rain auditory evoked repsonses (BAERs) were per-
ormed prior to transplantation and at scheduled in-
ervals posttransplant, and interpreted according to
he guidelines established by the American Clinical
europhysiology Society [26]. EEGs were considered
bnormal if focal or generalized slowing, spikes, or
harp waves were present. The ﬂash VEP was consid-
red normal if the P100 wave was present and abnormal
f it was absent. The BAERs were considered abnormal
f either the wave I-V interpeak latency was prolonged
r if any of the obligate wave forms (I, III, V) were
bsent. Nerve conduction studies were considered ab-
ormal if they showed prolongation of the distal latency,
ow amplitude, absent evoked response, or prolonged
-wave latency. Study results were interpreted by expert
hysicians blinded to the status of the patient.
tatistical Analysis
The probability of event-free survival (patient du-
ably engrafted with donor cells and alive) and the
ncidence of acute grade II-IV GVHD were calculated
y Kaplan-Meier analysis. Five baseline measures
BAERs, VEP, NCV, EEG, and brain MRI) were
valuated as predictors of posttransplant cognitive and
otor development. To evaluate these predictors a
ixed effects regression model was ﬁt for each base-
ine measure, with cognitive development as the out-
ome and age, baseline measure, and the interaction of
ge and baseline measure as the predictors. The
AERs, VEP, NCV, and EEG were entered as di-
hotomous variables coded as normal or abnormal as
escribed above. MRI Loes scores were evaluated on
After 5 years
of The Differential Ability Scales
Clinical Evaluation of Language Fundamentals 3—Third
Edition
PDMS-2 (up to 70 months developmental age) then the
Bruininks-Oserestsky Test of Motor ProficiencyScales
urth
condScales of Independent Behavior Revised (SIBR)
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D. Beam et al.668oth an ordinal scale (0-34) and dichotomous coded as
10 versus 11 or greater.
ESULTS
atients Characteristics
From April 2000 through November 2005, 12
oys with a median age at diagnosis of 7 years (neo-
ate to 9.75 years) were admitted to Duke University
edical Center for transplantation. One patient was
ispanic, 1 Asian, and 10 Caucasian. The median age
t initiation of chemotherapy was 7.1 years (range:
.36-11.7) and the median weight was 22 kg (range:
2.7-50.9), respectively (Table 2). One boy died while
eceiving chemotherapy but before receiving his
ransplant. Four boys received Lorenzo’s Oil [27]
rior to transplant, but none continued this therapy
uring or after transplantation.
onor Characteristics
All donor/recipient pairs were mismatched at 1 (n
) or 2 (n  8) HLA loci. Major ABO incompatibili-
ies were present in 3 donor/recipient pairs. The me-
ian number of nucleated cells per unit was 6.98 107
ells per kilogram (range: 2.83  107 to 14.19  107)
efore cryopreservation. UCB units delivered a me-
ian 5.66  107 cells/ kg (range: 2.54-11.9) based on
he postthaw count. The median number of CD34
nfused was 2.44  105 per kilogram (range: 0.39-
.16) (Table 2).
urvival, Engraftment, and GVHD
Twelve patients received conditioning but 1 died
n day 7 of shock and brain herniation likely sec-
ndary to adrenal crisis (Table 2). Eleven patients
ere successfully transplanted. The OS at 6.25
onths was 66.7% (95% conﬁdence interval 39.9-
3.3%) (Figure 1a). There were no events after this
ime point. The median follow up was 3.3 years
range: 12 days-6.3 years). Posttransplant, 2 patients
ied of progressive ALD (patients 7 and 10) and 1
atient died of severe VOD (patient 11).
Ten of 11 patients engrafted neutrophils in a me-
ian of 22.9 days (range: 13-49) and platelets in a
edian of 86.8 days (range: 55-227). Two patients
ould not be evaluated for platelet engraftment be-
ause they died while still requiring transfusions be-
ause of hemorrhagic cystitis or secondary effects of
iral reactivation therapy. One patient experienced
rimary graft failure, but engrafted after a second
CB transplant, 67 days after the ﬁrst transplant with
onditioning with cyclophosphamide and ATG (pa-
ient 9). Five of the 11 evaluable patients developed
rade I GVHD, 2 developed grade II, and 2 devel-
ped grade IV GVHD (Figure 1b). cGVHD oc-
urred in 2 patients (1 limited and 1 extensive) Ta P
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Outcomes of Unrelated UCBT for X-ALD 669Table 2, Figure 1c). The patient with extensive
GVHD experienced severe neurologic deteriora-
ion 2 years posttransplant. The patient developed
ew white matter changes on MRI and visual motor
nd cognitive deﬁcits, which temporarily improved
ith high-dose steroids and later stabilized on Et-
nercept. A brain biopsy showed diffusely increased
icroglia and reactive astrocytosis in the cortex and
hite matter, preservation of myelination, and no
vidence of lymphoproliferative disorder or active
igure 1. (a) Overall survival after transplantation. Kaplan-Meier
verall survival at 6.25 months was 66.7% (95% conﬁdence interva
n  10, 2 events). Cumulative incidence at day 100: 40.0% (95%
VHD (n  10, 2 events). Cumulative incidence at day 365: 10.0%
onﬁdence interval 0.0%-53.2%).LD. A presumptive diagnosis of brain GVHD was Hade and the patient stabilized with immunosup-
ressive therapy.
Myeloablative doses of oral Busulfan were used in
he conditioning regimen. Busulfan was administered
t 20-40 mg/m2/dose orally (based on age)  16 doses
n days 9 through 6, busulfan pharmacokinetics
ere measured after the ﬁrst dose, and subsequent doses
ere adjusted to target a steady state concentration of
00-900 ng/mL. Only 1 patient developed signs of grade
II-IV hepatic toxicity and VOD 9 days posttransplant.
tes of the probability of overall survival. Cumulative incidence of
-93.3%). (b) Cumulative incidence of acute GVHD grades II-IV
dence interval 7.5%-72.5%). (c) Cumulative incidence of chronic
conﬁdence interval 0.0%-29.6%) CINC at day 730: 22.9% (95%estima
l 39.9%
conﬁe died of progressive VOD on day 12.
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D. Beam et al.670europhysiologic Studies
VEP. VEP were available in 9 patients pretrans-
lant and 8 patients posttransplant. Pretransplant, 2 of
he patients had abnormal ﬁndings. Patient 1 had no
eproducible waveforms and lost all vision in the peri-
ransplant period. Patient 5 had prolonged absolute
atencies in the P100 waveform but has normal vision
osttransplant. Of the 7 remaining patients, the 3
ounger ones were normal pretransplant and re-
ained normal posttransplant. The other 4 patients,
ho were normal pretransplant, had no reproducible
aveforms or lost the P100 wave posttransplant. Two
f these patients (7 and 10) lost vision in the peritrans-
lant period. Patient 4 developed anisotropia but pre-
erved functional vision.
BAERs. BAERs were available in 10 patients pre-
ransplant and 7 posttransplant. Pretransplant, 8 pa-
ients had normal responses as well as normal hearing
s measured by serial behavioral audiometry (patients
-5, 10, 11, and 12). Abnormal results were seen in 2
atients (7 and 9) who demonstrated prolongation of
-V latency. Posttransplant, these 2 patients normal-
zed and 4 additional patients remained normal. One
atient who initially had normal BAERs and behav-
oral audiometry, developed prolongation of I-V la-
ency, a focal brainstem lesion on BAERs, and right
eripheral hearing loss (patient 4).
NCS. NCSs were available in 10 patients pretrans-
lant with normal ﬁndings in 9 of these patients (pa-
ients 1, 3-5, and 7-11). Posttransplant 4 of the 6
atients studied remain normal (patients 3, 4, 8, 9). Of
he other 2, 1 (patient 6) who was unable to walk,
howed pre- and posttransplant peripheral motor neu-
opathy and left peroneal nerve damage and the other
patient 10) developed a severe decrease in amplitude
nd latency posttransplant and died of progressive
isease.
EEGs. EEGs were available in 11 patients pre-
ransplant, of which 5 were normal (patients 2, 3, 4, 9,
nd 11). Of the remaining 6 patients, 1 showed diffuse
ackground slowing (patient 7), 1 had polymorphic
elta slowing in the right posterior quadrant (patient
0), 1 had intermittent right temporal slowing (patient
), 1 had frontal occipital slowing (patient 6), and the
dditional 2 patients had focal seizure spikes (patients
and 12). Posttransplantation, 8 patients were stud-
ed, 2 patients remained normal (patients 3 and 9), 1
howed temporal slowing (patient 4), and 5 patients
patients 1, 6-8, 10) with abnormal pretransplant EEG
rogressed to have focal seizure activity.
eurodevelopmental Function
Cognitive function. Of the 11 patients who were
ransplanted, 9 had normal to strong cognitive skills
patients 1-7, 9, and 11) and 2 were delayed pretrans-
lant (patients 8 and 10). Ten patients had follow-up sssessments posttransplant. Five patients (2-5, and 9)
ontinued to show average cognitive gains. Patient 8
ho had comorbid mental retardation at baseline re-
ained stable but has not gained new skills after the 2
ears of follow-up. Four patients who experienced
apid neurologic deterioration had scores in the spatial
rea 1-5 standard deviations lower than their verbal
cores (patients 1, 6, 7, and 10) (Figure 2a).
Adaptive behavior. This domain, unlike the others,
s measured by parent’s responses to a standardized
easure of the child’s independent and self-help abil-
ties. Nine patients were assessed pre and posttrans-
lant. Two other patients had a single visit: 1 pre-
ransplant and 1 posttransplant. Pretransplant, 10
atients had average skills. Of these, 2 were in the low
verage range and deteriorated during the peritrans-
lant period. Posttransplant 5 patients (1, 6, 7, 8, and
0) deteriorated rapidly and 1 patient (patient 4) lost
ost adaptive skills 2 years after transplant but re-
ained some function after treatment of presumed
VHD of the brain. Patients 2, 3, 5, and 9 remained
ormal (Figure 2b).
Language. Four patients had pretransplant and
osttransplant testing (patients 2, 3, 6, and 9), 2 pa-
ients had only pretransplant data (4 and 7), and 2 had
nly posttransplant data (5 and 8). Receptive and ex-
ressive language were normal to strong in all the
atients tested pretransplant. Of the 6 patients tested
osttransplant, 4 remain with average language skills
2, 3, 5, and 9), 1 (patient 8) deteriorated slightly after
ransplant, and 1 (patient 6) deteriorated rapidly after
ransplant and is not verbal (Figure 3c and d). One
atient (patient 4) was not formally tested but had no
ifﬁculties communicating. All patients were noted to
ave some degree of articulation difﬁculties pretrans-
lant that continued after transplantation.
Motor function. Eight patients were tested before
ransplant and 10 after transplant in the gross motor
rea (Figure 2e). Pretransplant, 4 patients had av-
rage skills (2, 3, 9, and 11) and 4 were delayed (4,
, 7, and 10). Posttransplant, 2 patients continue to
ave average gross motor skills (2 and 9), and 1 not
reviously tested has average skills 6 years posttrans-
lant (patient 5).
Pretransplant, patient 3 had average skills. How-
ver, he had hypotonia, mild ataxia, and posturing of 1
rm secondary to resection of low-grade astrocytoma
iscovered on initial MRI after diagnosis of ALD.
fter transplant, his motor function improved, and
ow, 4 years posttransplant, he only has a mild motor
elay. Of the remaining 6 patients followed posttrans-
lant, 1 was weak but stable for 2 years and then lost his
bility to ambulate because of presumed GVHD of the
rain. After treatment with immunosuppression, he sta-
ilized and regained ability to walk short distances with
walker (patient 4). Another patient is regainingtrength and is able to sit, stand, and walk with full
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Outcomes of Unrelated UCBT for X-ALD 671ssistance and adaptive equipment (patient 8). One pa-
ient is able to hold his head and sit up with assistance
patient 6). The other patient is unable to perform any
kills (patient 1). The 2 remaining patients died after
apid motor deterioration, spasticity, and inability to
erform any spontaneous movement (patients 7 and 10).
In the ﬁne motor area 7 children were tested. Two
atients had severe disease progression posttransplant
nd developed clasped thumbs (1 and 6), and the other
patients died (Figure 3f). The 3 youngest patients
ontinue to have normal ﬁne motor skills posttrans-
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igure 2. (a-f) Developmental function by domain. Each patient’s d
epresents typical population development. The gray area represenlant (patients 2, 3, and 9). The 3 older patients (4, 5, rnd 8) not formally tested, are able to write and use
heir hands without difﬁculty.
euroimaging
Brain MRI scans (MRI) were available in 11 pa-
ients pretransplant. The Loes scores ranged from 3-
3 with a median of 8. Of the 5 patients with Loes
cores 10, 2 died from progressive ALD (patients 7
nd 10), 2 deteriorated neurologically and are severely
ffected (patients 1 and 6), and 1 who had mental
tnempoleveD evitpadA
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D. Beam et al.672rea but had motor deterioration posttransplant (pa-
ient 8) (Figure 3a and b). Five of the 6 patients with
cores 10 are long-term survivors with favorable
eurodevelopmental outcomes, and 1 (patient 11) died
f transplant-related VOD. Four of the 5 patients
ave continued to learn and develop normally (pa-
ients 2, 3, 5, and 9), and 1 who has above average
ognitive abilities is having mild difﬁculties in speed of
rocessing and has deteriorated in the motor area
resumably from GVHD of the brain (patient 4).
redictors of Posttransplant Outcome
Five baseline measures (BAERs, VEP, NCV,
EG, and MRI) were evaluated as predictors of post-
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igure 3. (a) Cognitive development and pretransplant MRI Loes
cores. The green line represents typical development. Each blue
ine represents the longitudinal cognitive course of a surviving
atient with baseline Loes Scores 10. The red lines represent the
ongitudinal cognitive course of surviving patients with Loes Scores
10. The black and purple represent deceased patients. (b) Gross
otor development and pretransplant MRI Loes scores. The green
ine represents typical development. Each blue line represents the
ongitudinal motor course of a surviving patient with baseline Loes
cores 10. The red lines represent the longitudinal motor course
f surviving patients with Loes scores 10. The black and purple
epresent deceased patients. Note that motor scores are in general
ower than cognitive scores in (a).ransplant cognitive and motor outcome. As previ- susly described, pretransplant MRI Loes scores have
een found to be associated with poor prognosis
28,29]. Pretransplant Loes scores signiﬁcantly corre-
ated with longitudinal cognitive (P  .006) (Figure
a) and motor development (p  .014) (Figure 3b). Of
he 6 children with Loes scores 10, the 5 that sur-
ived continue to show normal cognitive develop-
ent. Of the 5 children with Loes scores 10, 4
howed rapid cognitive and neurologic deterioration
nd 2 of these 4 died. The ﬁfth patient (patient 9) who
ad comorbid mental retardation stabilized but has
ow function. Baseline neurophysiologic results failed
o show statistically signiﬁcant differences in predict-
ng cognitive or motor outcomes.
Interestingly, 4 of the 5 children with Loes scores
10 demonstrated signiﬁcant differences between the
erbal and nonverbal/spatial IQ at baseline. Con-
ersely, all 5 patients with scores 10 had no signiﬁ-
ant differences between the verbal and nonverbal/
patial IQ and continued to have normal cognitive
unction posttransplant. All patients with normal mo-
or function and Loes scores 10 continue to develop
ormal motor function.
ISCUSSION
We report the results of unrelated donor UCB
ransplantation in a group of 12 boys with cerebral
-ALD. Despite HLA mismatching, the transplant
rocedure yielded similar outcomes to those previ-
usly reported after HLA-matched bone marrow
ransplantation [4-7]. The probability of OS was
1.9% with the 3 younger children, demonstrating a
urvival of 100%.
There are several parameters that can be used to
redict outcome of patients with ALD after HSCT.
he pretransplant Loes score has been shown to cor-
elate with outcomes after bone marrow transplanta-
ion [28]. Age and pattern of demyelination in brain
RI have been reported to aid in predicting progres-
ion [29]. Previous studies have also reported that
atients with performance IQ 80 (also referred as
onverbal IQ) at baseline are signiﬁcantly more im-
aired posttransplant and those with parietal-occipital
attern demonstrate greater mean loss in their perfor-
ance IQ [7]. One of the objectives of this study was
o determine whether baseline Loes score was a strong
redictor of posttransplant cognitive and motor out-
omes. Ten patients were available for this analysis.
oes scores were found to be strong predictors of
utcome. Baseline nonverbal/spatial scores in combi-
ation with overall cognitive scores and Loes scores
ere as a group strongly associated with outcome.
owever, because our sample was not large, we did
ot report a deﬁnitive index combining these mea-
ures. Future studies will be needed to assess if the
c
c
w
p
c
r
a
o
p
i
m
z
t
t
8
w
e
u
p
a
f
o
A
d
m
p
n
l
y
A
T
s
c
h
c
n
c
c
d
s
w
i
i
r
c
p
y
a
w
i
p
s
A
t
T
c
a
c
o
g
v
a
C
H
R
1
1
1
Outcomes of Unrelated UCBT for X-ALD 673ombination of these measures will aid the clinician in
ounseling families regarding treatment outcomes
hen they are considering transplant.
A second objective was to ask if baseline neuro-
hysiologic studies, BAERs, VEP, EEG, and NCV,
orrelated with cognitive and motor outcomes. These
esults were mixed. The BAERs and NCV were not
lways associated with progressive neurologic deteri-
ration and became abnormal only later in the disease
rocess. The VEP and EEG became abnormal earlier
n the disease process. Most patients who had abnor-
alities in pretransplant EEGs developed clinical sei-
ures posttransplant and had poor outcome. However,
his ﬁnding was not statistically signiﬁcant. Most of
he children in our sample were10 years. As many as
0% of children this age have the parietal-occipital
hite matter pattern of involvement [29]. This may
xplain the early abnormalities seen in VEP.
In this study, myeloablative doses of busulfan were
sed in the conditioning regimen for transplant. In
revious studies, busulfan has been reported to cause
drenal insufﬁciency in healthy patients [30]. There-
ore, careful consideration should be given to the use
f busulfan in conditioning regimens in patients with
LD. All patients should be supplemented with stress
oses of hydrocortisone during the preparative regi-
en. Even after dilantin prophylaxis, busulfan ap-
eared to lower the seizure threshold and accelerate
eurologic deterioration. Myeloablative agents with
ow neurotoxicity need to be studied in the future.
This is the ﬁrst report that includes a cohort of
oung children transplanted before development of
LD symptomatology or progressive MRI changes.
hese children were referred for transplant because of
trong family history of cerebral X-ALD and MRI
hanges consistent with this disorder. Two patients
ad adrenal insufﬁciency and 1 had an astrocytoma as
omorbid conditions. Although these children have
ot reached the age at which cerebral X-ALD typi-
ally progresses, they tolerated the procedure well;
ontinue to have normal neurologic exams, typical
evelopment, and no additional changes in MRI
cans at 4, 6, and 8 years of age. In contrast, children
ho followed the present recommendation of wait-
ng until progressive MRI changes or abnormalities
n neurobehavioral testing are evident had increased
isk of rapid neurologic deterioration, transplant
omplications, and dismal outcome. This study sup-
orts the use of unrelated UCB transplantation in
oung asymptomatic patients to maximize survival
nd improve neurodevelopmental outcomes. The
indow of opportunity to treat can be easily missed
f there is no family history, and therefore it also
rovides support for inclusion of ALD in neonatal
creening programs.CKNOWLEDGMENTS
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